AI Article Synopsis
- A clinical trial tested Cefazedone, a new antibiotic, on 75 patients with gynecological issues and urinary tract infections, finding it effective against bacteria like E. coli.
- The treatment lasted 10-11 days with good outcomes in 71 patients and only minor side effects, namely slight diarrhea in 5 cases.
- No harmful effects on liver or kidney function were observed, and Cefazedone was well tolerated in over 90% of patients.
Article Abstract
A clinical trial on efficacy and tolerance of Cefazedone, a new semisynthetic Cephalosporine-derivate, was carried out in a gynaecological clinic on 75 patients. In 38 of these cases, besides the gynaecological affection, urinary tract infections were determined microbiologically (E. coli, P. mirabilis, klebsiella or enterococci). Inflammation of the lower abdominal area was established in the remaining 37 patients (adnexitis, pelvic peritonitis, endometritis, salpingitis). The average duration of treatment was 10 to 11 days. Cefazedone was injected intravenously twice a day, the daily dose was 2 to 4 g. The clinical assessment of the treatment was very good in 28 cases, good in 43 cases, moderate in 3 patients and poor in 1 case. All initially identified pathogens were eliminated after treatment. A slight transitory diarrhea was observed in 5 cases. There were no further side-effects. The values of gamma-GT, serum-creatinin, hemoglobin and erythrozytes were controlled before and after medication and showed no detremental effect of the drug. The local tolerance of Cefazedone was good in more than 90% of the cases treated.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Risk factors of beta-lactam anaphylaxis in Korea: A 6-year multicenter retrospective adult case-control study.
World Allergy Organ J
September 2021
Drug Safety Monitoring Center, Seoul National University Hospital, Seoul, South Korea.
Background: Beta-lactams (BLs) are commonly used antibiotics and leading causative agents of drug-induced anaphylaxis. Few studies on the culprit drugs and risk factors of BL-induced anaphylaxis are available. Our goal was to evaluate the culprit drugs and compare the risk factors in patients with BL-induced anaphylaxis to matched tolerant controls in a hospital setting.
View Article and Find Full Text PDF[Cefazedone-results of a multicentre clinical test (author's transl)].
MMW Munch Med Wochenschr
March 1980
Cefazedone (Refosporin) was tested for efficacy and tolerance in 1161 patients. The trial was interrupted or unsuitable for evaluation in 54 cases. Diagnostical characteristics of the remaining 1107 patients tested for tolerance were: therapeutical and prophylactic use in surgery (37,5%) infections of the bronchial tract (30.
View Article and Find Full Text PDF[Pharmacokinetics and tolerance of Cefazedone compared with Cefazoline (author's transl)].
Wien Med Wochenschr
February 1980
In a randomized cross over study Cefazoline and Cefazedone were administered i.v. as injection of 2 minutes duration and as infusion of 30 minutes duration.
View Article and Find Full Text PDFArticle Synopsis
- A clinical trial tested Cefazedone, a new antibiotic, on 75 patients with gynecological issues and urinary tract infections, finding it effective against bacteria like E. coli.
- The treatment lasted 10-11 days with good outcomes in 71 patients and only minor side effects, namely slight diarrhea in 5 cases.
- No harmful effects on liver or kidney function were observed, and Cefazedone was well tolerated in over 90% of patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!